Collaborative Team Doubles Number of In Vitro Patient-Derived Cancer Models Available for Research
Dana-Farber Investigators Develop Protein Degrader Discovery Platform and Find First-in-Kind Metabolically Activated Molecular Glue Degrader
U.S. News & World Report Names Dana-Farber Brigham Cancer Center #1 Locally, #3 Nationally for 2026-2027
U.S. News & World Report Recognizes Fox Chase Cancer Center Among Nation’s Best Hospitals for Cancer Care
It Takes a Community for a Winn Scholar to Build a Clinical Trial
Inspiration for Patients and Peers
FDA Approves Personalized Blood-Test Guided Immunotherapy for Bladder Cancer, Backed by Dana-Farber Science
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Surgery With or Without Neoadjuvant Chemotherapy in High-Risk RetroPeritoneal Sarcoma (STRASS2)
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)
Three-Drug Treatment Shows Promise for Patients with Rare Blood Cancer BPDCN
Doximity Ask AI May Be Smart, but Trusted Answers Still Depend on Physicians Like Dr. Cohn
Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer
Showing 1 - 15 of 1075 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...72 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
